Novo Nordisk Research Centre Oxford, Oxford, UK.
Novo Nordisk A/S, Måløv, Denmark.
Nat Commun. 2024 Apr 1;15(1):2817. doi: 10.1038/s41467-024-46663-4.
Osteoarthritis (OA) is increasing in prevalence and has a severe impact on patients' lives. However, our understanding of biomarkers driving OA risk remains limited. We developed a model predicting the five-year risk of OA diagnosis, integrating retrospective clinical, lifestyle and biomarker data from the UK Biobank (19,120 patients with OA, ROC-AUC: 0.72, 95%CI (0.71-0.73)). Higher age, BMI and prescription of non-steroidal anti-inflammatory drugs contributed most to increased OA risk prediction ahead of diagnosis. We identified 14 subgroups of OA risk profiles. These subgroups were validated in an independent set of patients evaluating the 11-year OA risk, with 88% of patients being uniquely assigned to one of the 14 subgroups. Individual OA risk profiles were characterised by personalised biomarkers. Omics integration demonstrated the predictive importance of key OA genes and pathways (e.g., GDF5 and TGF-β signalling) and OA-specific biomarkers (e.g., CRTAC1 and COL9A1). In summary, this work identifies opportunities for personalised OA prevention and insights into its underlying pathogenesis.
骨关节炎(OA)的患病率正在上升,对患者的生活造成了严重影响。然而,我们对导致 OA 风险的生物标志物的理解仍然有限。我们开发了一种预测 OA 诊断五年风险的模型,整合了来自英国生物库的回顾性临床、生活方式和生物标志物数据(19120 名 OA 患者,ROC-AUC:0.72,95%CI(0.71-0.73))。在诊断前,更高的年龄、BMI 和非甾体抗炎药的处方对增加 OA 风险预测的贡献最大。我们确定了 14 个 OA 风险特征亚组。这些亚组在另一组评估 11 年 OA 风险的患者中得到了验证,88%的患者被唯一分配到 14 个亚组之一。个体 OA 风险特征由个性化的生物标志物来描述。组学整合表明了关键的 OA 基因和途径(例如 GDF5 和 TGF-β 信号)以及 OA 特异性生物标志物(例如 CRTAC1 和 COL9A1)的预测重要性。总之,这项工作为个性化 OA 预防提供了机会,并深入了解了其潜在的发病机制。